Doctoral School Department, "Victor Babes" University of Medicine and Pharmacy Timisoara, 300041 Timisoara, Romania.
Department of Obstetrics and Gynecology, "Victor Babes" University of Medicine and Pharmacy Timisoara, 300041 Timisoara, Romania.
Nutrients. 2024 May 28;16(11):1662. doi: 10.3390/nu16111662.
This systematic review evaluates the hypothesis that optimal serum magnesium levels may enhance remission rates in Crohn's disease (CD) and considers whether magnesium supplementation could be beneficial in CD management. This review aims to synthesize available evidence concerning the impact of serum magnesium on disease remission in CD, and to analyze the effectiveness and mechanistic roles of magnesium supplementation. Adhering to the PRISMA guidelines, we searched PubMed, Web of Science, and Scopus up to January 2024 using MeSH terms and free-text queries related to CD and magnesium. The inclusion criteria were studies that investigated serum magnesium levels, effects of supplementation, and the inflammatory mechanisms in CD remission. From the 525 records identified, eight studies met the inclusion criteria after the removal of duplicates and irrelevant records. These studies, conducted between 1998 and 2023, involved a cumulative sample of 453 patients and 292 controls. Key findings include significantly lower serum magnesium levels in CD patients (0.79 ± 0.09 mmol/L) compared to controls (0.82 ± 0.06 mmol/L), with up to 50% prevalence of hypomagnesemia in CD patients observed in one study. Notably, CD patients, particularly men, exhibited lower magnesium intake (men: 276.4 mg/day; women: 198.2 mg/day). Additionally, low magnesium levels correlated with increased sleep latency (95% CI -0.65 to -0.102; = 0.011) and decreased sleep duration (95% CI -0.613 to -0.041; = 0.028). Another key finding was the significant association between low serum magnesium levels and elevated CRP levels as an indicator of CD disease activity. The findings support the hypothesis that serum magnesium levels are significantly lower in CD patients compared to healthy controls and suggest that magnesium supplementation could improve CD management by enhancing remission rates and sleep quality. However, more rigorous, evidence-based research is necessary to define specific supplementation protocols and to fully elucidate the role of magnesium in CD pathophysiology.
本系统评价评估了这样一个假设,即最佳血清镁水平可能会提高克罗恩病(CD)的缓解率,并考虑镁补充是否对 CD 管理有益。本综述旨在综合现有关于血清镁对 CD 疾病缓解影响的证据,并分析镁补充的有效性和机制作用。根据 PRISMA 指南,我们使用与 CD 和镁相关的 MeSH 术语和自由文本查询,在 PubMed、Web of Science 和 Scopus 上检索了截至 2024 年 1 月的文献。纳入标准为研究血清镁水平、补充效果以及 CD 缓解中的炎症机制的研究。在去除重复和不相关记录后,从 525 条记录中确定了 8 项符合纳入标准的研究。这些研究于 1998 年至 2023 年期间进行,共涉及 453 名患者和 292 名对照者的累积样本。主要发现包括 CD 患者的血清镁水平显著低于对照组(0.79±0.09mmol/L 比 0.82±0.06mmol/L),一项研究中观察到高达 50%的 CD 患者存在低镁血症。值得注意的是,CD 患者,特别是男性,摄入的镁较少(男性:276.4mg/天;女性:198.2mg/天)。此外,低镁水平与增加的睡眠潜伏期(95%CI-0.65 至-0.102;=0.011)和减少的睡眠时间(95%CI-0.613 至-0.041;=0.028)相关。另一个关键发现是低血清镁水平与升高的 CRP 水平之间存在显著关联,CRP 水平是 CD 疾病活动的指标。这些发现支持这样一个假设,即与健康对照组相比,CD 患者的血清镁水平显著降低,并表明镁补充可能通过提高缓解率和改善睡眠质量来改善 CD 管理。然而,需要更严格、基于证据的研究来确定具体的补充方案,并充分阐明镁在 CD 病理生理学中的作用。